Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials

Shanghai Archives of Psychiatry

Volumn 28, Issue 2, 2016, Pages 64-71

  Zheng, Wei ^a   Xiang, Ying Qiang ^b,c   Ungvari, Gabor S ^d,e   Chiu, Helen F k ^f   Ng, Chee H ^g   Wang, Ying ^h   Xiang, Yu Tao ⁱ  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h University of Macau   (Macao)

ⁱ University of Macau   (Macao)

Author keywords

Adjunctive treatment; Cognitive function; Depression; Huperzine A; Meta analysis

Indexed keywords

EID: 84978906246     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.11919/j.issn.1002-0829.216003     Document Type: Article

References (26)

1. Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS. The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. J Neurosci Res. 2015; 93(1): 104-120. doi: http://dx.doi.org/10.1002/jnr.23473
2. Srikumar BN, Raju TR, Shankaranarayana Rao BS. The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats. Neuroscience. 2006; 143(3): 679-688. doi: http://dx.doi.org/10.1016/ j.neuroscience.2006.08.041
3. Pelton GH, Andrews H, Roose SP, Marcus SM, D'Antonio K, Husn H, et al. Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. Contemp Clin Trials. 2014; 37(2): 200-208. doi: http://dx.doi.org/10.1016/j.cct.2013.11.015
4. Islam MR, Moriguchi S, Tagashira H, Fukunaga K. Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice. Neuroscience. 2014; 272: 116-130. doi: http://dx.doi.org/10.1016/j.neuroscience.2014.04.046
5. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011; 116(1): 6-17
6. McDermott CL, Gray SL. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. The Annals of pharmacotherapy. 2012; 46(4): 599-605. doi: http://dx.doi.org/10.1345/aph.1Q445
7. Matsuda T, Ago Y, Takuma K. [Pharmacological profiles of galantamine: the involvement of muscarinic receptor]. Nihon shinkei seishin yakurigaku zasshi (Japanese Journal of Psychopharmacology). 2012; 32(1): 1-8. Japanese
8. Ma X, Tan C, Zhu D, Gang DR, Xiao P. Huperzine A from Huperzia species-an ethnopharmacolgical review. J Ethnopharmacol. 2007; 113(1): 15-34. doi: http://dx.doi.org/10.1016/j.jep.2007.05.030
9. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci. 2006; 27(12): 619-625. doi: http://dx.doi.org/10.1016/j.tips.2006.10.004
10. Xing SH, Zhu CX, Zhang R, An L. Huperzine A in the treatment of Alzheimer's disease and vascular dementia: a metaanalysis. Evid Based Complement Alternat Med. 2014; 2014: 363985. doi: http://dx.doi.org/10.1155/2014/363985
11. Kongs SK, Thompson LL, Iverson GL, Heaton RK. Wisconsin Card Sorting Test-64 Card Version (WCST-64). Odessa, FL: Psychological Assessment Resources; 2000
12. Chelune GJ, Bornstein RA, Prifitera A. The Wechsler Memory Scale-Revised. Springer: Advances in Psychological Assessment; 1990. p. 65-99
13. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry; 1960. 23: 56-62
14. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depression & Anxiety. 2001; 13(4): 166-178. doi: http://dx.doi.org/10.1002/da.1033.abs
15. World Health Organization. WHOQOL: Measuring Quality of Life. Division of Mental Health and Prevention of Substance Abuse. World Health Organization; 1997
16. Guy, W. ECDEU assessment manual. In: US Department of Health. Education and Welfare, Alcohol. Drug Abuse and Mental Health Administration. Rochville, MD: National Institute of Mental Health; 1976
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539-1558. doi: http://dx.doi.org/10.1002/sim.1186
18. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-188. doi: http://dx.doi.org/10.1016/0197-2456(86)90046-2
19. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. UK, Chichester: John Wiley & Sons; 2008
20. Gao YF, Li J, Meng HQ, Luo QH, Hu H, Du L. [Effects of huperzine on cognition function and life quality of patients with depression]. Chongqing Yi Xue. 2007; 36(6): 483-485. Chinese. doi: http://dx.chinadoi.cn/10.3969/j.issn.1671-8348.2007.06.001
21. Yang ZB, Deng XM, Zhang GX, Yu XR. [The study of huperzine combined with fluoxetine on cognition function of patients with depression]. Lin Chuang Jing Shen Yi Xue Za Zhi. 2010; 20(6): 418-419. Chinese
22. Liu SZ, Wang PJ, Yin A J, Dang XJ, Guang H. [Effects of huperzine A combined with venlafaxine for patients with depression]. Zhongguo Shi Yong Yi Yao. 2010; 5(11): 151-152. Chinese. doi: http://dx.chinadoi.cn/10.3969/j.issn.1673-7555.2010.11.116
23. Chinese Medical Association. [Chinese Mental Disorders Classification and Diagnostic Criteria, Third Edition (CCMD-3)]. Jinan: Shandong Science and Technology Press; 2001. Chinese
24. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel ploy asymmetry in meta-analyses of randomized controlled trials. BMJ. 2011; 343: d4002. doi: http://dx.doi.org/10.1136/bmj.d4002
25. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924-926. doi: http://dx.doi.org/10.1136/bmj.39489.470347.AD
26. Zheng W, Xiang YQ, Li XB, Ungvari GS, Chiu HFK, Sun F, et al. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. Hum Psychopharmacol: Clinical and Experimental. 2016; doi:10.1002/hup.2537